 | • レポートコード：MRC2303M072 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療機器 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査資料によると、世界のニューロインターベンショナル装置市場規模が、予測期間中に年平均成長率7.7%で拡大すると予測されています。本書は、ニューロインターベンショナル装置の世界市場にフォーカスし、最新動向と今後の市場性などをまとめており、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別（動脈瘤コイル・塞栓装置、脳バルーン血管形成術・ステント装置、神経血栓除去装置、その他）分析、用途別（虚血性脳卒中、脳動脈瘤、動静脈奇形・瘻孔、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来の動向などが掲載されています。また、Abbott、Johnson & Johnson Services, Inc (CERENOVUS)、Medtronic、MicroPort Scientific Corporation、Penumbra, Inc.、Stryker、Terumo Corporation、W. L. Gore & Associates, Inc.など、主要企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のニューロインターベンショナル装置市場規模：製品別 - 動脈瘤コイル・塞栓装置の市場規模 - 脳バルーン血管形成術・ステント装置の市場規模 - 神経血栓除去装置の市場規模 - その他の市場規模 ・世界のニューロインターベンショナル装置市場規模：用途別 - 虚血性脳卒中における市場規模 - 脳動脈瘤における市場規模 - 動静脈奇形・瘻孔における市場規模 - その他における市場規模 ・世界のニューロインターベンショナル装置市場規模：地域別 - 北米のニューロインターベンショナル装置市場規模 アメリカのニューロインターベンショナル装置市場規模 カナダのニューロインターベンショナル装置市場規模 メキシコのニューロインターベンショナル装置市場規模 … - ヨーロッパのニューロインターベンショナル装置市場規模 イギリスのニューロインターベンショナル装置市場規模 フランスのニューロインターベンショナル装置市場規模 ドイツのニューロインターベンショナル装置市場規模 … - アジア太平洋のニューロインターベンショナル装置市場規模 中国のニューロインターベンショナル装置市場規模 インドのニューロインターベンショナル装置市場規模 日本のニューロインターベンショナル装置市場規模 … - 南米/中東のニューロインターベンショナル装置市場規模 ブラジルのニューロインターベンショナル装置市場規模 アルゼンチンのニューロインターベンショナル装置市場規模 南アフリカのニューロインターベンショナル装置市場規模 … - その他地域のニューロインターベンショナル装置市場規模 ・競争状況 ・市場機会・将来の動向 |
The neurointerventional devices market is expected to register a CAGR of 7.7% over the forecast period.
The outbreak of COVID-19 affected the neurointerventional devices market in several ways, as it limited the intensive care unit (ICU) beds and ventilation sites owing to the necessity of postponing elective and/or complex cases. Moreover, as per the analysis, there were considerable variations in the management of neuro interventions during and after the pandemic. For instance, as per the report published by Cardiovascular Revascularization Medicine in July 2022, to ascertain the overall effect on vascular intervention trials halted by the COVID-19 pandemic, more research is required in the field of vascular intervention. Hence, the market is expected to rapidly rebound to pre-pandemic levels nonetheless, as a result of the restart of all healthcare facilities, a drop in COVID-19 cases, and follow-up trials on vascular intervention after COVID-19.
The major factors contributing to the growth of the market are the increasing target patient population, ongoing product development and commercialization, and rising research activities in the field of neurovascular therapies.
Neurointerventional devices are used by medical professionals specializing in the domain of the central nervous system (CNS). It is usually done by neuroradiologists, neurosurgeons, and neurologists exploring the endovascular approach to treat the vascular diseases of the central nervous system. The burden of vascular diseases associated with the central nervous system in the target population primarily drives the usage of devices. According to WSO data updated in June 2022, about 12.2 million (12,224,551) people will experience a stroke by the end of the year. In addition, the intracranial aneurysm, also known as a cerebral or brain aneurysm, is a bulging, weakened area in the wall of an artery in the brain. According to data from the National Health Service (NHS), England, updated in April 2022, the prevalence of brain aneurysms could be as high as 1 in 20 people, and brain aneurysms can develop in anyone at any age, but are more common in people over the age of 40. Furthermore, according to updated data from the Brain Aneurysm Foundation in January 2022, an estimated 6.5 million Americans have an unruptured brain aneurysm. About 30,000 people in the United States suffer a brain aneurysm rupture each year. A brain aneurysm ruptures every 18 minutes. The consistently high volume of patients with CNS vascular diseases approaching healthcare facilities is expected to drive the demand for neurointerventional devices.
Similarly, the new device developments and approvals will help the market grow during the study period. For instance, in April 2021, Medtronic received approval from the US FDA for the Pipeline Flex Embolization Device with Shield Technology. The Pipeline Flex Embolization Device diverts blood flow away from a brain aneurysm.
Such factors are altogether contributing to the market’s growth over the analysis period. However, the stringent regulations and dearth of skilled neurosurgeons are the primary limitations to the growth of the studied market.
Neurointerventional Devices Market Trends
Ischemic Stroke Segment is Expected to Hold Major Share of the Market Over the Forecast Period
Ischemic stroke is characterized by the sudden loss of blood circulation to an area of the brain, resulting in a corresponding loss of neurologic function. The major factors that positively impact the segment include the increase in the incidence of ischemic stroke and the developments made by various major players in the market.
For instance, as per the WSO’s Global Stroke Fact Sheet 2022, there are over 7.6 million new ischemic strokes each year. Globally, over 62% of all incident strokes are ischaemic strokes. This shows a significant rise in cases every year that need proper neurointerventions through neurointerventional devices. Thus, the increase in the incidence of vascular diseases like ischaemic stroke drives the neurointerventional devices market over the forecast period.
Similarly, the recent developments in the devices used for ischemic stroke drove the market growth during the study period. For instance, in June 2022, Rapid Medical enrolled the first patient in the DISTALS Study. The trial is the first-ever FDA investigational device exemption (IDE) trial to examine the safety and effectiveness of mechanical thrombectomy in distal stroke with TIGERTRIEVER 13, the smallest and most adjustable thrombectomy device. With a wide range of applications linked to arterial-based disease correction, there is significant usage of neurointerventional devices. Similarly, in February 2022, MicroPort NeuroTech Limited (MicroPort NeuroTech) received marketing approval from the NMPA for its self-developed Neurohawk Stent Thrombectomy Device (Neurohawk). The Neurohawk is the clot stent retriever launched by MicroPort NeuroTech for acute ischemic stroke treatment.
Thus, given the above-mentioned facts, the studied market is expected to grow over the forecast period.
North America is Expected to Hold a Significant Share in the Market Over the Forecast Period
The United States contributes the most to the North American region and is responsible for the dominance of the region across the world. North America, with its advanced healthcare infrastructure across the majority of places and the presence of many medical device companies well-connected with hospitals, primarily boosts the growth of this market.
According to the statistics published by the CDC in April 2022, more than 795,000 Americans have strokes. Each year, 610,000 of these instances are discovered to be new. About 87% of all strokes are ischemic strokes, in which blood flow to the brain is blocked. Hence, the increase in stroke cases in the region increases the demand for neurointerventional devices for proper management, which helps in the growth of the market during the forecast period.
Furthermore, new device approvals and launches also help the market grow. For instance, in February 2022, CERENOVUS launched EMBOGUARD, a next-generation balloon guide catheter to be used in endovascular procedures, including those for patients with acute ischemic stroke. The EMBOGUARD balloon guide catheter is designed to optimize the removal of clots by controlling blood flow locally during MT procedures. Thus, all the new device approvals and launches help the market grow in the region.
Thus, all the aforementioned factors are expected to boost the market’s growth over the forecast period.
Neurointerventional Devices Market Competitor Analysis
The neurointerventional devices market is moderately competitive and consists of several major players. The companies have identified consistent growth opportunities in the treatment of endovascular-based diseases via neurointerventional devices. Some of the major companies in this segment include Abbott, Johnson & Johnson Services, Inc. (CERENOVUS), Medtronic, Stryker, Penumbra, Inc., MicroPort Scientific Corporation, Terumo Corporation, and W. L. Gore & Associates, Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions & Market Defination
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Target Patient Population
4.2.2 Ongoing Product Development and Commercialization
4.2.3 Rising Research Activities in the Field of Neurovascular Therapies
4.3 Market Restraints
4.3.1 Stringent Regulations
4.3.2 Dearth of Skilled Neurosurgeons
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – by USD million)
5.1 By Product
5.1.1 Aneurysm Coiling & Embolization Devices
5.1.2 Cerebral Balloon Angioplasty and Stenting Systems
5.1.3 Neurothrombectomy Devices
5.1.4 Other Devices
5.2 By Application
5.2.1 Ischemic Stroke
5.2.2 Cerebral Aneurysms
5.2.3 Arteriovenous Malformation and Fistulas
5.2.4 Other Diseases
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott
6.1.2 Johnson & Johnson Services, Inc (CERENOVUS)
6.1.3 Medtronic
6.1.4 MicroPort Scientific Corporation
6.1.5 Penumbra, Inc.
6.1.6 Stryker
6.1.7 Terumo Corporation
6.1.8 W. L. Gore & Associates, Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS